Table 3. Antiretroviral agents available for first-line ART, ART anchor agent, reported reason for major modification and selected switched-to ART regimen by country income grouping.
| AHOD | TAHOD | TAHOD | |
| N (%) | High Income | Low Income | |
| N (%) | N (%) | ||
| Number of different ARV agents used for initial ART regimen * | |||
| N(t)RTI | 9 | 7 | 7 |
| NNRTI | 2 | 2 | 2 |
| PI | 8 | 9 | 5 |
| II | 1 | 1 | 0 |
| Initial ART regimen | |||
| 2 N(t)RTI+NNRTI | 574 (61) | 852 (68) | 1976 (97) |
| 2 N(t)RTI+PI | 279 (30) | 364 (29) | 67 (3) |
| 2 N(t)RTI+II | 25 (3) | 6 (0) | 0 (0) |
| Other (non-standard, e.g. 3 N(t)RTI) | 67 (7) | 38 (3) | <5 (0) |
| Number of switches from initial ART regimen | 350 | 352 | 259 |
| Reported reason for modification | |||
| Treatment failure | 47 (19) | 45 (13) | 73 (29) |
| Adverse event/toxicity | 97 (38) | 141 (41) | 107 (42) |
| Patient decision/Physician decision | 110 (43) | 162 (47) | 76 (30) |
| Not reported | 96 | <5 | <5 |
| Modified ART regimen | |||
| Initial ART: 2 N(t)RTI+NNRTI | |||
| 2 N(t)RTI+NNRTI | 48 (30) | 67 (34) | 85 (35) |
| 2 N(t)RTI+PI | 75 (47) | 69 (35) | 66 (27) |
| 2 N(t)RTI+II | 6 (4) | 0 (0) | 0 (0) |
| Other (non-standard) | 29 (18) | 63 (32) | 93 (38) |
| Initial ART: 2 N(t)RTI+PI | |||
| 2 N(t)RTI+PI | 42 (27) | 80 (65) | <5 (10) |
| 2 N(t)RTI+NNRTI | 64 (41) | 30 (24) | 9 (65) |
| 2 N(t)RTI+II | 9 (6) | <5 (5) | 0 (0) |
| Other (non-standard) | 41 (26) | 8 (6) | <5 (25) |
*
Individual ARV agents with each class where less than 5 people initiated where excluded from the total count.
N(t)RTI = Nucleos(t)ide Reverse Transcriptase Inhibitor, NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor, PI = Protease Inhibitors, II = Integrase Inhibitor.